Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Astana Economic Forum 2015 was held at 21st and 22nd of May. A central theme of the Forum was “Infrastructure – a driver of sustainable economic growth”.
The world economy is facing major cross currents – oil prices, exchange rate adjustments, divergence of monetary policies and the legacies of the Great Recession of 2009. The global economic growth remains weak and moderate while potential output growth has declined.
To view the Multimedia News Release, go to http://www.multivu.com/players/uk/7568051-recommendations-astana-economic-forum/
UBS launched its first global brand campaign since 2009 today, reflecting the firm’s strategic transformation and future direction. Featuring a distinctive brand film as well as advertising with images by Annie Leibovitz, the campaign also refreshes the strong UBS brand with a contemporary look and feel. The external launch follows a three-month internal campaign that inspired unprecedented rates of employee engagement.
“The brand campaign is an expression of the successful strategic transformation UBS has undergone over the past four years,” said Sergio P. Ermotti, Group Chief Executive Officer. “Reflecting the strategic transformation through our branding gives us additional momentum.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7612551-ubs-launches-global-brand-campaign/
Heute fand im „Maison de la Chimie“ in Paris die Pressekonferenz #ChangeTheNumbers der L’Oréal-Stiftung statt. Dort wurden die Ergebnisse einer exklusiven internationalen Studie vorgestellt, die gemeinsam mit dem Meinungsforschungsinstitut „Opinion Way“ durchgeführt wurde. Ziel der Untersuchung war es, die Gründe für das Ungleichgewicht in der Wissenschaft zwischen Frauen und Männern besser zu verstehen sowie Hindernisse aufzudecken, denen Frauen bei einer Karriere in der Wissenschaft gegenüberstehen.
David Macdonald, Direktor des Förderprogramms For Women in Science von L’Oréal betonte auf der Veranstaltung, dass sich die Öffentlichkeit nicht darüber bewusst sei, wie stark die Vorurteile über Frauen in der Wissenschaft noch immer in den Köpfen der Menschen verankert sind. Heute bewegt sich der Frauenanteil in der Wissenschaft nach wie vor auf geringem Niveau: Nur 30 % aller Forscher sind weiblich.1
Als Ergänzung zu dieser Studie hat die L’Oréal-Stiftung darüber hinaus Erfahrungsberichte von Preisträgerinnen, die im Rahmen des For Women in Science Programmes ausgezeichnet wurden, hinzugezogen. Besonders stolz ist die Stiftung auf die Unterstützung von Elizabeth Blackburn, L’Oréal-UNESCO For Women in Science Preisträgerin und Nobelpreisträgerin für Physiologie oder Medizin 2009. Elizabeth Blackburn
To view the multimedia release go to:
http://www.multivu.com/players/de/7624751-loreal-foundation-results-study/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
blu, the brand which pioneered electronic vaping, will launch a new global brand and marketing campaign, under the tagline “Just You & blu.”
The campaign celebrates the individualistic lifestyles of blu consumers – each representing an independent spirit, carving their own paths in life and enjoying blu along the way. The “Just You & blu” campaign will feature television and cinema commercials, print ads and billboards, as well as digital and social content. “Just You & blu” will premier April 4 in the United States, United Kingdom, Italy and France.
blu has been the innovator in electronic vaping since the brand was introduced in 2009, and continues to evolve as the ultimate consumer vaping experience.
“blu is the most iconic brand in the electronic vaping category,” said John Wardley, Chief Marketing Officer for Fontem Ventures, blu’s parent company. “This campaign will serve to solidify and grow the leadership position blu enjoys in the US and the UK, while introducing the brand to new consumers in our two launch markets, Italy and France.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7801651-just-you-and-blu/
Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme.
Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year1. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes/
2009'da TÜBİTAK Bilim ve Teknik Dergisi'ndeki Darwin skandalından (http://www.hurriyet.com.tr/gundem/111...) sonra başlayan evrim tartışmaları ekranlara da yansımıştı. Celal Şengör ise jeoloji profesörü olmasına rağmen ilahiyat öğrencilerinin bilim ve evrim karşıtı (daha doğrusu ezberleyip geldikleri) sorularına ustalıkla cevap vermişti.
Programın başlarında Şengör'ün insanın evrimini anlatma çabalarına rağmen, soru-cevap bölümüne gelindiğinde eğitim sisteminin kurbanı bir neslin Dunning-Kruger sendromundan nasıl nasiplendiğine tanık olduk. Bu kısımdaki genç de konuyla ilgili en ufak bir bilgisi olmamasına rağmen bir bilim insanına kafa tutmak için ezber bellediği soruları kendinden çok emin bir şekilde soruyor ve sorularına tek tek cevap geldikçe daha da hırslanıyor. Konuyu öğrenmek ve anlamak için sormadığı çok açık değil mi? O salonda kulaklarını gerçeklere kapatmış kitlenin toplumun çoğunluğunu oluşturması da bir o kadar acı değil mi? Anlamaya ihtiyaç duymuyoruz, çünkü bize ezberletilenlerin güvenilir alanında olmak rahatlık veriyor. Gerçekleri anlamak içinse ayrı bir efor sarfetmek ve o konforlu alanı aşmak gerekmekte.
